The Role of Nafamostat Mesylate in Continuous Renal Replacement Therapy among Patients at High Risk of Bleeding
Authors:
- 17 January 2012
- journal article
- research article
- Published by Taylor & Francis in Renal Failure
- Vol. 34 (3) , 279-285
Abstract
Continuous renal replacement therapy (CRRT) has emerged as the preferred dialysis modality for critically ill patients with acute kidney injury. The objectives of this retrospective study were to assess the effect of nafamostat on circuit patency of CRRT and the safety regarding bleeding complications in patients at high risk of bleeding. We conducted a retrospective study of 243 CRRT patients at high risk of bleeding. We started CRRT without anticoagulation, and nafamostat was used if hemofilter lifespan was less than 12 h. The average hemofilter lifespan was measured before and after drug infusion to evaluate the efficacy of nafamostat. The frequency and number of red blood cell (RBC) transfusions were measured to assess the safety of nafamostat. Of the 243 patients, 62 (25.5%) received nafamostat. In nafamostat group, the hemofilter lifespan was lengthened from 10.2 (7.5–13.0) h to 19.8 (12.6–26.6) h after drug infusion (p < 0.001). The hemofilter lifespan was 27.5 (17.5–38.2) h in anticoagulation-free group. The frequency of RBC transfusion during CRRT did not differ between the nafamostat group and the anticoagulation-free group (71% vs. 70%, p = NS). The median number of RBC units transfused per CRRT day was also not different between the two groups [0.7 (0.5–1.0) units/day vs. 0.7 (0.4–1.1) units/day; p = NS]. The use of nafamostat in patients at high risk of bleeding who require CRRT effectively lengthened the filter survival time without an increase in RBC transfusion. However, 74.5% of patients at high risk of bleeding maintained an acceptable CRRT hemofilter lifespan without circuit anticoagulation.Keywords
This publication has 24 references indexed in Scilit:
- THE CLINICAL APPLICATION OF CRRT—CURRENT STATUS: Anticoagulation for Continuous Renal Replacement TherapySeminars in Dialysis, 2009
- Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care systemJournal of Critical Care, 2005
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modesKidney International, 2000
- Regional citrate anticoagulation in continuous venovenous hemodiafiltrationAmerican Journal of Kidney Diseases, 2000
- Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleedingKidney International, 1999
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996
- Mechanisms of hyperkalemia caused by nafamostat mesilateGeneral Pharmacology: The Vascular System, 1995
- Inhibition of tissue factor-factor VIIa by nafamostat mesilate; a reply to the rebuttalThrombosis Research, 1995
- Pharmacological Studies of FUT-175, Nafamstat Mesilate I. Inhibition of Protease Activity in in Vitro and in Vivo ExperimentsThe Japanese Journal of Pharmacology, 1984